Changes in Hong Kong stocks | AI Pharmaceuticals' commercialization ability gradually highlights Jetai Technology-P (07666) surged more than 7% to lead

The Zhitong Finance App learned that most biomedical concepts strengthened this morning. Among them, Jetai Technology-P (07666) surged more than 7% to lead AI pharmaceutical stocks. As of press release, it rose 7.68% to HK$11.22, with a turnover of HK$9.521 million.

According to the news, leading domestic AI pharmaceuticals are going overseas at an accelerated pace, and their commercialization capabilities are continuously being recognized by overseas capital and giants. In the first half of this year, Jietai Technology and Deerfield reached a pre-clinical TCE cooperation, with a down payment of 20 million US dollars and a total transaction amount of 1.6 billion US dollars. Also, according to incomplete statistics, since 2026, Insili Intelligence has reached a total of 10 external licensing and cooperative R&D transactions, with a total transaction scale of close to 10 billion US dollars. The cooperation between Jingtai Holdings and Dovetree's AI platform is progressing smoothly, and a second payment of $19 million has been received.

It is worth mentioning that Jietai Technology previously announced that the AiTEM artificial intelligence formulation innovation platform independently developed by the company will complete localization deployment at Hengrui Pharmaceutical to accelerate the efficiency of pharmaceutical formulation development. This cooperation marks the continuous commercialization of the AITEM artificial intelligence formulation platform driven by nanoForge, and also means that nanoForge will accelerate its evolution as AI4S R&D infrastructure.